Search Result

Results for "

CD47-SIRPα interaction

" in MedChemExpress (MCE) Product Catalog:

By Targets:	CD47 (13) Transmembrane Glycoprotein (1)
By Research Areas:	Cancer (13) Infection (1) Inflammation/Immunology (1)

Inhibitors & Agonists

Peptides

Inhibitory Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-P99950

Evorpacept ALX148	CD47	Cancer
Evorpacept (ALX148) is a high-affinity *CD47*-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the *CD47-SIRPα* immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia .

HY-P990033

Anzurstobart CC-95251; BMS-986351	CD47	Cancer
Anzurstobart is a *CD47/SIRPα* inhibitor with human SIRPα K_d of 0.0541 nM and human SIRPα IC₅₀ of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .

HY-143224B

NCGC00138783 TFA	CD47	Cancer
NCGC00138783 TFA is a selective inhibitor targeting *CD47/SIRPα* axis, with an IC₅₀ of 50 μM. NCGC00138783 TFA directly blocks the interaction between CD47 and SIRPα axis .

HY-P11097

Pep-20	CD47	Cancer
Pep-20 is a *CD47/SIRPα* blocking peptide with K_D values of 2.91 and 3.63 μM for human and mouse CD47, respectively. IC₅₀ values for blocking the human and mouse CD47/SIRPα interaction are 24.56 and 12.03 μM, respectively. Pep-20 has antitumor activity .

HY-P990289

Anti-Mouse CD172a Antibody (P84)	Transmembrane Glycoprotein	Infection
Anti-Mouse CD172a Antibody (P84) is a rat-derived anti-mouse CD172a IgG1 κ type antibody inhibitor. Anti-Mouse CD172a Antibody (P84) blocks CD47-SIRPα interaction and thereby augments cell phagocytosis. Anti-Mouse CD172a Antibody (P84) can be used for the researches of infection and immunology, such as salmonella typhimurium infection .

HY-P991057

STI-6643	CD47	Cancer
STI-6643 is a fully human IgG4 antibody that targets *CD47. STI-6643 blocks CD47-SIRPα* interaction, and enables macrophage-mediated phagocytosis of tumor cells. STI-6643 shows anti-tumor activity in mouse lymphoma xenograft models. STI-6643 can be used for the research of Burkitt's lymphoma, solid tumors, relapsed or refractory tumors, and lymphoma. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-143224

NCGC00138783	CD47	Cancer
NCGC00138783 is a selective inhibitor targeting *CD47/SIRPα* axis, with an IC₅₀ of 50 µM. NCGC00138783 directly blocks the interaction between CD47 and SIRPα axis .

HY-151132

Glutaminyl cyclases-IN-1 IsoQC-IN-1	CD47	Cancer
Glutaminyl cyclases-IN-1 (IsoQC-IN-1) is a potent glutaminyl cyclases (QC) inhibitor with IC₅₀ values of 12 nM and 73 nM for human QC and isoQC, respectively. Glutaminyl cyclases-IN-1 can selectively interfere with the interaction of *CD47/SIRPα* through isoQC inhibition, and enhances the increased phagocytic activity of both THP-1 and U937 macrophages .

HY-P991062

Gentulizumab Gensci-059	CD47	Cancer
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets *CD47. Gentulizumab displays strong binding to CD47* in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991561

AO-176	CD47	Cancer
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the *CD47*-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .

HY-P10813

ZLIRTLHEWY	CD47	Inflammation/Immunology Cancer
ZLIRTLHEWY is a potent peptide *CD47/SIRPα* interaction inhibitor. ZLIRTLHEWY is promising for research of cancers .

HY-143224A

NCGC00138783 free base	CD47	Cancer
NCGC00138783 free base is a selective inhibitor targeting *CD47/SIRPα* axis, with an IC₅₀ of 50 µM. NCGC00138783 free base directly blocks the interaction between CD47 and SIRPα axis .

HY-P991927

ZL-1201	CD47	Cancer
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .

HY-P991924

CO-1	CD47	Cancer
CO-1 is an IgG4 anti-CD47 antibody. CO-1 not only enhances themacrophage phagocytosis activity but also induces a unique and fast form of programmed celldeath (PCD) in cancer cells directly through ligation of CD47. CO-1 has anticancer activity against hematologic malignancies such as acute lymphoblastic leukemia .

Cat. No.	Product Name	Target	Research Area

HY-P11097

Pep-20	CD47	Cancer
Pep-20 is a *CD47/SIRPα* blocking peptide with K_D values of 2.91 and 3.63 μM for human and mouse CD47, respectively. IC₅₀ values for blocking the human and mouse CD47/SIRPα interaction are 24.56 and 12.03 μM, respectively. Pep-20 has antitumor activity .

HY-P10813

ZLIRTLHEWY	CD47	Inflammation/Immunology Cancer
ZLIRTLHEWY is a potent peptide *CD47/SIRPα* interaction inhibitor. ZLIRTLHEWY is promising for research of cancers .

Cat. No.	Product Name	Target	Research Area	Image

HY-P99950

Evorpacept ALX148	CD47	Cancer
Evorpacept (ALX148) is a high-affinity *CD47*-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the *CD47-SIRPα* immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia .

HY-P990033

Anzurstobart CC-95251; BMS-986351	CD47	Cancer
Anzurstobart is a *CD47/SIRPα* inhibitor with human SIRPα K_d of 0.0541 nM and human SIRPα IC₅₀ of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies .

HY-P990289

Anti-Mouse CD172a Antibody (P84)	Transmembrane Glycoprotein	Infection
Anti-Mouse CD172a Antibody (P84) is a rat-derived anti-mouse CD172a IgG1 κ type antibody inhibitor. Anti-Mouse CD172a Antibody (P84) blocks CD47-SIRPα interaction and thereby augments cell phagocytosis. Anti-Mouse CD172a Antibody (P84) can be used for the researches of infection and immunology, such as salmonella typhimurium infection .

HY-P991057

STI-6643	CD47	Cancer
STI-6643 is a fully human IgG4 antibody that targets *CD47. STI-6643 blocks CD47-SIRPα* interaction, and enables macrophage-mediated phagocytosis of tumor cells. STI-6643 shows anti-tumor activity in mouse lymphoma xenograft models. STI-6643 can be used for the research of Burkitt's lymphoma, solid tumors, relapsed or refractory tumors, and lymphoma. The isotype control for STI-6643 can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991062

Gentulizumab Gensci-059	CD47	Cancer
Gentulizumab (Gensci-059) is a humanized IgG4 antibody that targets *CD47. Gentulizumab displays strong binding to CD47* in both human and monkey, and effectively inhibits the CD47-SIRPα interaction. Gentulizumab exhibits a potent antitumor activity. The isotype control for Gentulizumab can refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .

HY-P991561

AO-176	CD47	Cancer
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. AO-176 induces tumor phagocytosis through blocking the *CD47*-SIRPα interaction. AO-176 preferentially binds to tumor versus normal cells and directly kills tumor by a cell autonomous mechanism not ADCC (antibody-dependent cell-mediated cytotoxicity). AO-176 demonstrates dose-dependent antitumor activity in tumor xenograft models. AO-176 can be used for the researches of cancer, such as lymphoma .

HY-P991927

ZL-1201	CD47	Cancer
ZL-1201 is a recombinant humanized monoclonal anti-CD47 IgG4 antibody. ZL-1201 disrupt the CD47-SIRPα interaction. ZL-1201 modulates the tumor microenvironment. ZL-1201 promotes tumor-associated macrophage phagocytic activity. ZL-1201 substantially enhances phagocytosis by M2 macrophages, but not by M1 macrophages. ZL-1201 in combination with both mAb and chemotherapy achieves the maximal antitumor effects in a variety of solid tumor models. ZL-1201 can be used in the study of lymphoma, breast cancer, ovarian cancer, head and neck squamous cell carcinoma, and gastric cancer .

HY-P991924

CO-1	CD47	Cancer
CO-1 is an IgG4 anti-CD47 antibody. CO-1 not only enhances themacrophage phagocytosis activity but also induces a unique and fast form of programmed celldeath (PCD) in cancer cells directly through ligation of CD47. CO-1 has anticancer activity against hematologic malignancies such as acute lymphoblastic leukemia .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.